4D Molecular Therapeutics
4dmoleculartherapeutics.com · Technology · FDMT
Ranked 431 of 2,047 companies in the study
- Visibility7
- Citations0
- Sentiment100
- Site quality87
- AI readiness36
AI assistants rarely name 4D Molecular Therapeutics. They mention the company in 1 of 60 answers. Its overall score is 40 out of 100, ranking 431st of 2,047 companies and 69th of 273 in the Technology sector. The website passes 5 out of 14 technical checks for AI tool readiness.
We asked 15 unbranded questions about the technology market: none named 4D Molecular Therapeutics. AI assistants named it in 1 of 60 answers (1.7%). The typical technology company is named in 10.0% of answers. By how often it is named, 4D Molecular Therapeutics ranks 211 of 273 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
273 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“Which innovative genetic medicine platforms show promise for large market diseases?”
Based on recent developments in the field, several innovative genetic medicine platforms show significant promise for large market diseases:
Key Technology Platforms
The major technology platforms include adeno-associated viral (AAV) vectors for in vivo gene delivery, CRISPR/Cas9 gene editing for precise genetic correction, and emerging in vivo gene writing approaches that promise programmable genome modification without ex vivo cell processing.
AAV-Based Platforms
Viral vector platforms dominate the market segment with the largest revenue share of 58.1% in 2024. 4D Molecular Therape …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtPassed
An llms.txt that tells language models what the site offers.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 36 of 100 · 97% of checks could run · checked on October 5, 2026 · 4dmoleculartherapeutics.com · 2,047 companies scanned
5 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Passedllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Which emerging non-genetic treatment options compare to gene medicines for rare diseases?
- Are there programs that help patients access advanced gene therapies at lower out-of-pocket costs?
- What should healthcare providers look for when evaluating next-generation genetic medicine solutions?
- Are advanced gene therapies with customized vectors worth considering for patients with unmet medical needs?
- What advancements are shaping the future landscape of curative intent genetic therapies?
- Which patient populations benefit most from precision-targeted gene therapies?
- What are the main alternatives to gene therapy for inherited metabolic disorders?
- What are common challenges in delivering genetic medicines to hard-to-reach tissues?
- How does an engineered viral vector platform differ from naturally occurring viral vectors in gene therapy?
- What factors influence the cost of genetic medicines for serious inherited diseases in the US?
- AAV-based gene delivery vs. lentiviral vectors: which is better for central nervous system disorders?
- Which innovative genetic medicine platforms show promise for large market diseases?
- What are the best gene therapy options for treating rare genetic diseases in adults?
- How are engineered vectors being used to target previously untreatable genetic disorders?
- Why might a gene therapy not provide lasting effects in a patient with a hereditary condition?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.